Showing 1,961 - 1,980 results of 2,181 for search '"medical researcher"', query time: 0.08s Refine Results
  1. 1961
  2. 1962
  3. 1963
  4. 1964
  5. 1965

    Socioeconomic indicators related to the global burden of breast cancer in women in 2020: an analysis of WHO data by Tingting XU, Ruoyu YANG, Jingjing LI, Yiying FANG

    Published 2024-11-01
    “…The mean values of the 10 selected indicators representing national socioeconomic development were as follows: 2 138.06 ± 7 465.03 million for total female population, 26.58 ± 17.12 μg/m3 for mean annual urban particulate matter concentration; 63.97 ± 57.32 per 10 000 population for density of physicians, 4.01 ± 4.11 per 10 000 population for density of pharmacists, 4.11 ± 4.32 US dollars for net official development assistance received by the medical research and basic health sector per capita, 63.65 ± 20.31 for average of 13 International Health Regulations Core Capacity Scores, 10. 41 ± 5.17% for the percentage of government health expenditure, 68.00 ± 28.65% for the percentage of the population using safely managed sanitation services, 66.05 ± 95.28 million US dollars in official development assistance (ODA) provided through government-coordinated expenditure plans specifically for water and sanitation, and 0.587 ± 0.190 for the inequality-adjusted Human Development Index (HDI). …”
    Get full text
    Article
  6. 1966

    Experiences of Oral Corticosteroid Use and Adverse Effects: A National Cross-Sectional Survey of People with Asthma by Jones AW, McDonald VM, McLoughlin RF, Vella TM, Flynn AW, Blakey JD, Wolfenden L, Hew M, Upham JW, Thomas D, Bardin P, Holland AE

    Published 2025-01-01
    “…Arwel W Jones,1 Vanessa M McDonald,2– 5 Rebecca F McLoughlin,2– 4 Teresa M Vella,6 Anthony W Flynn,7 John D Blakey,8,9 Luke Wolfenden,10,11 Mark Hew,12 John W Upham,13,14 Dennis Thomas,2,4 Philip Bardin,15 Anne E Holland1,2,16 1Respiratory Research@Alfred, Monash University, Melbourne, VIC, Australia; 2Centre of Excellence in Treatable Traits, University of Newcastle, Newcastle, NSW, Australia; 3School of Nursing and Midwifery, University of Newcastle, Newcastle, NSW, Australia; 4Hunter Medical Research Institute Asthma and Breathing Program, Newcastle, NSW, Australia; 5Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia; 6Brand and Engagement, Asthma Australia, Brisbane, QLD, Australia; 7Research, Information and Evaluation, Asthma Australia, Melbourne, VIC, Australia; 8Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia; 9Medical School, Curtin University, Perth, WA, Australia; 10Hunter New England Population Health, Wallsend, NSW, Australia; 11School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia; 12Allergy, Asthma & Clinical Immunology, Alfred Health, Melbourne, VIC, Australia; 13Frazer Institute, University of Queensland, Brisbane, QLD, Australia; 14Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, QLD, Australia; 15Monash Lung Sleep Allergy & Immunology, Monash University and Medical Centre, Clayton, VIC, Australia; 16Physiotherapy Department, Alfred Health, Melbourne, VIC, AustraliaCorrespondence: Arwel W Jones, Respiratory Research@Alfred, School of Translational Medicine, Monash University, Alfred Centre, Melbourne, VIC, 3004, Australia, Email arwel.jones@monash.eduPurpose: Oral corticosteroids (OCS) are an effective treatment for severe uncontrolled asthma or asthma exacerbations, but frequent bursts or long-term use carry serious and sometimes irreversible adverse effects, or complications such as adrenal insufficiency upon discontinuation. …”
    Get full text
    Article
  7. 1967

    Assessing Mental Illness Referral Request Acceptance: A Nationwide E-Referral Data From Saudi Arabia by Alharbi AA, Aljerian NA, Alghamdi HA, Binhotan MS, Alsultan AK, Arafat MS, Aldhabib A, Aloqayli AI, Alwahbi EB, Horner RD

    Published 2025-02-01
    “…Abdullah A Alharbi,1 Nawfal A Aljerian,2– 4 Hani A Alghamdi,5 Meshary S Binhotan,4,6 Ali K Alsultan,2 Mohammed S Arafat,2 Abdulrahman Aldhabib,2 Ahmed I Aloqayli,2 Eid B Alwahbi,2 Ronnie D Horner7 1Family and Community Medicine Department, Faculty of Medicine, Jazan University, Jazan City, Kingdom of Saudi Arabia; 2Medical Referrals Centre, Ministry of Health, Riyadh, Kingdom of Saudi Arabia; 3Emergency Medical Services Department, College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Science, Riyadh, Kingdom of Saudi Arabia; 4King Abdullah International Medical Research Centre, Riyadh, Kingdom of Saudi Arabia; 5Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia; 6Emergency Medical Services Department, College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia; 7Health Services Research and Administration Department, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USACorrespondence: Meshary S Binhotan, Emergency Medical Services Department, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Riyadh, 22490, Kingdom of Saudi Arabia, Email hotanm@ksau-hs.edu.saBackground and Objective: Mental disorders significantly impact quality of life and life expectancy, representing a leading cause of global disease burden. …”
    Get full text
    Article
  8. 1968

    Effect of Buyang Huanwu Decoction Foot Bath on Pulmonary Rehabilitation of Patients with Chronic Obstructive Pulmonary Disease at Stable Phase by HUANG Huirong, HAN Xueqi, LIU Qinyu, XUE Jialu, YU Zhenling, CHEN Bin, MIAO Shaofang, CHEN Shuifeng

    Published 2021-10-01
    “…At both the before treatment and after treatment for two weeks, the percentage of forced expiratory volume in 1 second to predicted value (FEV1%pred) and forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) were used to evaluate the changes of pulmonary function in COPD patients at stable phase; the change of locomotor ability was observed by 6-minute walk distance (6MWD); the changes in the degree of dyspnea were assessed using the dyspnea scale of modified British Medical Research Council (mMRC); the chronic obstructive pulmonary disease assessment test (CAT) was used to observe the changes of patients' quality of life; the anxiety inventory for respiratory disease (AIR) was used to evaluate the change of anxiety. …”
    Get full text
    Article
  9. 1969

    Case of phenotype of optic nerve atrophy due to mutation in С19orf12 gene (neurodegeneration with the brain iron accumulation (nbia)) by M.E. Ivanova, V.V. Kadyshev, D.S. Atarshchikov, I.V. Zolnikova, N.P. Akchurina, N.K. Serova, F.A. Konovalov, E.R. Lozier, E.A. Pomerantseva, N.V. Vetrova, D. Barh, L.M. Balashova, J.M. Salmasi

    Published 2020-03-01
    “…Burdenko National Medical Research Center of Neurosurgery, Moscow, Russian <br> Federation</b> </p> <p> <b><sup>6 </sup>Independent Clinical Bioinformatics Laboratory, Moscow, Russian Federation</b> </p> <p> <b><sup>7 </sup>Center for Genetics and Reproductive Medicine “Genetiko”, Moscow, Russian <br> Federation</b> </p> <p> <b><sup>8 </sup>Institute of Integrative Omics and Applied Biotechnology (IIOAB), Bangalore, India</b> </p> <p> <b><sup>9</sup> Non-profit partnership International Scientific and Practical Center for the Proliferation <br> of Tissues of Russia, Moscow, Russian Federation</b> </p> <p> <b><sup>10</sup>Pirogov Russian National Research Medical University, Moscow, Russian Federation</b> </p> <p> <i>The article describes the clinical case of optic atrophy due to a homozygous mutation in exon 3 of the C19orf12 gene (chr19: 30193863AACAGCCCCCCG&gt; A, rs515726204), the frequency of which in the ExAC control sample is 0.0074. …”
    Get full text
    Article
  10. 1970
  11. 1971
  12. 1972
  13. 1973
  14. 1974
  15. 1975
  16. 1976
  17. 1977
  18. 1978
  19. 1979
  20. 1980